IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells.
Wu W, Chia T, Lu J, Li X, Guan J, Li Y, Fu F, Zhou S, Feng Y, Deng J, Zou J, Sun J, Yao Y, Ling X, Wu Z, Zhang Y, Xu J, Wang F, Liang X, Wu M, Liu H, Chen B, He K.
Wu W, et al. Among authors: yao y.
Nat Cancer. 2023 Sep;4(9):1309-1325. doi: 10.1038/s43018-023-00612-0. Epub 2023 Aug 7.
Nat Cancer. 2023.
PMID: 37550516